Radiolabeled farnesyl-protein transferase inhibitors
AssigneeMerck & Co., Inc.
InventorsHugh D. Burns, Wai-Si Eng, Raymond E. Gibson
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward radiolabeled farnesyl-protein transferase inhibitor compounds which are useful to label FPTase in assays, whether cell-based, tissue-based or in whole animal. The tracers can also be used in competitive binding assays to obtain information on the interaction of unlabeled FTIs with FPTase.
Claims8
A radiolabeled compound which is selected from:
- ##STR80## or a pharmaceutically acceptable salt thereof.
A radiolabeled compound of the formula ##STR81## or pharmaceutically acceptable salt thereof, which has been radiolabeled with a radionuclide selected from .sup.3 H, .sup.11 C, .sup.18 F, .sup.125 I and .sup.123 I, provided that if .sup.3 H or .sup.11 C is selected, the radionuclide is incorporated at the terminal methyl moiety of the side chain attached to the C5 position of the piperazinone ring.
Dependencies are inferred from the claim text.